Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CMRX 
Chimerix Inc (CMRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CMRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 41.71% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 798.27M USD | Price to earnings Ratio - | 1Y Target Price 8.54 |
Price to earnings Ratio - | 1Y Target Price 8.54 | ||
Volume (30-day avg) 6415252 | Beta 0.32 | 52 Weeks Range 0.75 - 8.53 | Updated Date 03/31/2025 |
52 Weeks Range 0.75 - 8.53 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -43073.69% |
Management Effectiveness
Return on Assets (TTM) -33.64% | Return on Equity (TTM) -56.17% |
Valuation
Trailing PE - | Forward PE 1.21 | Enterprise Value 666147691 | Price to Sales(TTM) 3765.43 |
Enterprise Value 666147691 | Price to Sales(TTM) 3765.43 | ||
Enterprise Value to Revenue 3142.21 | Enterprise Value to EBITDA 1.03 | Shares Outstanding 93803800 | Shares Floating 78738010 |
Shares Outstanding 93803800 | Shares Floating 78738010 | ||
Percent Insiders 6.69 | Percent Institutions 52.49 |
Analyst Ratings
Rating 4.8 | Target Price 8.4 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Chimerix Inc
Company Overview
History and Background
Chimerix, Inc. was founded in 2000. It is a biopharmaceutical company focused on the development and commercialization of novel, oral antivirals to address unmet medical needs. The company initially focused on developing drugs for viral infections in immunocompromised patients.
Core Business Areas
- Pharmaceutical Development: Chimerix focuses on researching, developing, and commercializing antiviral drugs, primarily targeting severe or life-threatening viral infections. Previously, the company focused on small molecule antivirals. They have since pivoted to licensing their products.
Leadership and Structure
Details about the specific leadership team and organizational structure for Chimerix, Inc. would be found on their official investor relations website. It is publicly traded. Typically there is a CEO, CFO, and other C-level executives, along with a board of directors.
Top Products and Market Share
Key Offerings
- TEMBEXA (brincidofovir): TEMBEXA is an oral antiviral for the treatment of human smallpox disease in adult and pediatric patients. In 2021, Chimerix sold its worldwide rights to TEMBEXA to Emergent BioSolutions for up to $361 million, including royalties. Competitors for smallpox treatments include SIGA Technologies (STGA) with Tpoxx.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and strong competition. The antiviral market is driven by the emergence of new viral threats, the increasing prevalence of drug-resistant viruses, and the growing immunocompromised patient population.
Positioning
Chimerix positions itself as a company focused on developing and commercializing novel antivirals. Their focus on addressing unmet needs in the antiviral space, particularly for immunocompromised patients, differentiates them. The company has transitioned to licensing its assets rather than direct commercialization.
Total Addressable Market (TAM)
The overall pharmaceutical market is valued at over a trillion dollars globally, with the antiviral segment representing a significant portion. Chimerix's addressable market depends on the specific indications of its products, such as smallpox for TEMBEXA, and the prevalence of those diseases. Emergent Biosolutions now positions Temebxa within the TAM after acquiring the rights.
Upturn SWOT Analysis
Strengths
- Specialized focus on antiviral development
- Prior regulatory approvals for its products (e.g., TEMBEXA)
- Intellectual property portfolio (though some assets have been sold or licensed)
- Experienced management team (based on historical data - team turnover can change things).
Weaknesses
- Limited product pipeline following asset sales
- Reliance on partnerships and licensing agreements
- Financial performance heavily dependent on milestone payments and royalties
- Smaller market capitalization compared to major pharmaceutical players
Opportunities
- Potential for new antiviral drug discoveries and development
- Partnerships with larger pharmaceutical companies to commercialize its products
- Expansion into new geographic markets
- Addressing emerging viral threats (e.g., monkeypox, future pandemics)
Threats
- Competition from established pharmaceutical companies with larger resources
- Regulatory hurdles and clinical trial failures
- Patent expirations and generic competition
- Changes in government healthcare policies and reimbursement rates
Competitors and Market Share
Key Competitors
- STGA
- MRK
- GILD
Competitive Landscape
Chimerix is a smaller player in the antiviral market compared to larger pharmaceutical companies like Merck and Gilead. Its competitive advantage lies in its specialized focus and potential for innovative antiviral drugs, but it faces challenges in terms of resources and market reach. The above competitors compete within similar therapeutic areas, not necessarily direct product overlap.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent due to drug development successes and failures, as well as strategic shifts in business model.
Future Projections: Future growth projections are highly uncertain and depend on the success of its current and future licensing agreements and new antiviral discoveries.
Recent Initiatives: Recent initiatives may include new licensing agreements, drug discovery programs, and partnerships. Consult their recent financial statements and press releases for specific details.
Summary
Chimerix, Inc. is a biopharmaceutical company undergoing significant changes after selling its main assets. Its future success depends heavily on its ability to generate revenue through partnerships and licensing agreements and discover new antivirals. The company's financial performance is volatile. Investors should carefully monitor its licensing deals and pipeline progress. The company is shifting from a development company to a license holding company.
Similar Companies
- STGA
- MRK
- GILD
- EBS
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Press Releases
- Third-party financial data providers (e.g., Yahoo Finance, Google Finance)
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change. It's important to conduct your own research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Chimerix Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2013-04-11 | CEO, President & Director Mr. Michael T. Andriole M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 79 | Website https://www.chimerix.com |
Full time employees 79 | Website https://www.chimerix.com | ||
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.